Related references
Note: Only part of the references are listed.Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
mTOR in breast cancer: Differential expression in triple-negative and non-triple-negative tumors
S. Walsh et al.
BREAST (2012)
mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours
Atsuko Kasajima et al.
ENDOCRINE-RELATED CANCER (2011)
Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer
Jae Hong No et al.
GYNECOLOGIC ONCOLOGY (2011)
mTOR Activation in Well Differentiated Pancreatic Neuroendocrine Tumors: A Retrospective Study on 34 Cases
Chen-Fei Zhou et al.
HEPATO-GASTROENTEROLOGY (2011)
Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder
Chih-Hao Sun et al.
HISTOPATHOLOGY (2011)
Molecular mechanisms of liver regeneration and protection for treatment of liver dysfunction and diseases
Masato Fujiyoshi et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2011)
Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Victor M. Rivera et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung
Luisella Righi et al.
ENDOCRINE-RELATED CANCER (2010)
Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan
Tetsuhide Ito et al.
JOURNAL OF GASTROENTEROLOGY (2010)
The Pathologic Classification of Neuroendocrine Tumors A Review of Nomenclature, Grading, and Staging Systems
David S. Klimstra et al.
PANCREAS (2010)
The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement
Guenter Kloeppel et al.
VIRCHOWS ARCHIV (2010)
Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro
Silvia Darb-Esfahani et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
A Fuller Understanding of Pancreatic Neuroendocrine Tumours Combined with Aggressive Management Improves Outcome
S. L. Ong et al.
PANCREATOLOGY (2009)
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
T. R. Halfdanarson et al.
ANNALS OF ONCOLOGY (2008)
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Augusto Villanueva et al.
GASTROENTEROLOGY (2008)
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
Monica M. Mita et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma
Beata Herberger et al.
CLINICAL CANCER RESEARCH (2007)
New drug development in digestive neuroendocrine tumors
I. Duran et al.
ANNALS OF ONCOLOGY (2007)
The mTOR pathway in the control of protein synthesis
Xuemin Wang et al.
PHYSIOLOGY (2006)
Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins
XM Wang et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
mTOR and P70S6 kinase expression in primary liver neoplasms
F Sahin et al.
CLINICAL CANCER RESEARCH (2004)
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth
DA Altomare et al.
ONCOGENE (2004)
Share Paper
